41 results about "Antibody therapy" patented technology

The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.

The present application relates to the technical field of biotechnology, in particular to a programmed death receptor ligand 2 monoclonal antibody and application thereof. The present application provides a PD-L2 monoclonal antibody, amino acid sequences of three CDR regions of a heavy chain thereof; amino acid sequences of three CDR regions of a light chain thereof; or amino acid sequences obtained by substitution, deletion or addition of one or more amino acids of the amino acid sequences, or amino acid sequences functionally identical or similar to the amino acid sequences; or amino acid sequences having at least 80% homology with the sequences. The present application widens the possibility of antibody therapy for blocking PD1 / PD1 ligand, and compared with existing PD-L2 monoclonal antibodies, the 8E3 antibody has unique amino acid sequences and CDR region sequences, high affinity and high specificity. The 8E3 antibody can be used in ELISA, Western blot and flow cytometry detection, and has wide application.

The invention discloses a biomarker for monitoring the curative effect of a PD-1 antibody of a PD-L1Positive gastric cancer patient, and relates to the technical field of biomedical detection, and the biomarker is laminin gamma 2. According to the invention, the laminin gamma2 is used as a novel biomarker for monitoring the curative effect of the PD-1 treatment antibody of the PD-L1Positive gastric cancer patient, experiments prove that the serum level of the laminin gamma2 is higher than that of healthy people in the gastric cancer patient and is in positive correlation with a prognosis related factor sPD-L1, the tissue expression of the PD-L1Positive patient is higher, and the serum level of a person without PD-1 antibody treatment response is higher; it is proved that the marker has good progress monitoring value, treatment reaction differences can be effectively distinguished, and the blank of lack of PD-1 antibody curative effect monitoring markers for patients of the type is filled up.

Provided for are compositions and methods for treating amyloid related imaging abnormalities (ARIA) with selective Janus kinase (JAK) inhibitors in Alzheimer's disease (AD) patients or patients with other with neurodegenerative disease or cerebral amyloid angiopathy-related inflammation (CAAri) undergoing anti-amyloid therapy, including anti- amyloid antibody therapies. Particularly useful are JAK inhibitors selective against JAK1 and tyrosine kinase 2 (TYK2).

This invention discloses a bispecific nanobody targeting CXCL1 and PD-L1 and its applications, belonging to the fields of antibody engineering and bioengineering technology. The bispecific nanobody targeting CXCL1 and PD-L1 comprises at least one nanobody recognizing CXCL1 and one nanobody recognizing PD-L1, with the nanobody monomers linked by a linker. The bispecific nanobody targeting PD-L1 / CXCL1 provided by this invention has a unique structure, enabling it to specifically recognize and bind to both CXCL1 and PD-L1. It achieves an affinity of 1.08 nM for CXCL1 and 1.09 nM for PD-L1, effectively preventing immune escape-induced resistance to antibody therapy, making it suitable for a wider range of patients, and providing a new approach for CRC treatment.

To provide tumor-associated antigens suitable for targeted antibody therapy against cancer.SOLUTION: Antigen binding molecules that specifically bind ALPPL2 and ALPP, but not ALPL and ALPI are provided. Also provided are chimeric molecules and pharmaceutical compositions comprising the antigen-binding molecules, methods of reducing the expression or activity of ALPPL2 in cancer cells, and methods of treating cancers in a subject.SELECTED DRAWING: None

Targeting immunosuppressive B cell populations using bispecific or multivalent targeting molecules presents a potential pathway for therapeutic interventions that effectively modulate antitumor immune responses and improve therapeutic outcomes. Therefore, we provide engineered antibody-based therapeutics that can effectively and selectively target immunosuppressive B cell populations for the treatment of cancer. [Solution] A multispecific antibody is provided comprising a CD19 antigen-binding component configured to bind to CD19 and a CD38 antigen-binding component configured to bind to CD38, wherein the CD19 antigen-binding component comprises an antibody or an antigen-binding fragment thereof, and the CD38 antigen-binding component comprises an antibody or an antigen-binding fragment thereof.

This invention discloses a photothermal synergistic tumor stem cell inhibition system, its preparation method, and its applications. Addressing the current lack of effective treatments for large / unresectable GBM and its strongly immunosuppressive microenvironment, this invention constructs an injectable hydrogel platform (MIN-PPIC@iGel) integrating multiple key functions. This platform achieves a synergistic therapeutic model involving photothermal ablation for local tumor reduction, inhibition of residual GBM stem cells (GSCs), and activation of dendritic cells (DCs)-mediated anti-tumor immunity. Cellular experiments show that this invention can synergistically kill GL261 cells, significantly inhibit tumor stem cells and malignant phenotypes, induce significant ICD, and enhance DC maturation and activation effects. In a large-volume orthotopic GBM mouse model, a single intratumoral injection of MIN-PPIC@iGel combined with short-term near-infrared light irradiation doubled survival; further combination with antibody therapy unexpectedly achieved long-term tumor-free survival in 50% of mice, providing a new strategy for the local treatment of unresectable GBM.

An immune related adverse event marker and a kit. The immune related adverse event marker comprises CD183. The immune related adverse event marker can effectively predict immune related adverse events caused by programmed death receptor 1 antibody / programmed death-ligand antibody therapy, thereby facilitating intervention and treatment of immune related adverse events.

The present disclosure provides compositions comprising a designed ankyrin repeat protein (DARPin) for use in treating Shiga toxin (Stx)-producing Escherichia coli (STEC) and related diseases, including hemolytic uremic syndrome (HUS). The high thermostability and high microbial expression yield make DARPin an attractive alternative to antibody therapeutics. The present disclosure provides monomer proteins, dimer proteins, and trimer proteins, as well as pharmaceutical compositions and methods utilizing the same.

The present invention relates to interleukin 18 (IL-18) antibody therapies, low dose formulations of anti-IL-18 neutralizing antibodies, and the use of such formulations for the treatment of IL-18 related diseases by subcutaneous administration. The invention further relates to the use of said anti-IL-18 neutralizing antibody low-dose formulations in the treatment of e.g., adult pathogenic Stetill Disease (AOSD) or systemic pathogenic juvenile idiopathic arthritis (SoJIA, SoJIA, SoJIB, SoJIA, SoJIB, SoJIA, SoJIA, SoJIA, SoJIA, the present invention relates to the use thereof in Still disease such as Still disease (e.g., juvenile Still disease), atopic eczema or atopic dermatitis (AD), inflammatory bowel disease such as ulcerative colitis (UC) and Crohn's disease (CD), and eosinophilic esophagitis (EoE).

The present invention relates to a composition and method capable of effectively predicting the therapeutic responsiveness of a subject to an antibody therapeutic agent for asthma, using blood EDN levels or urine EDN levels. In particular, the present invention can significantly increase the efficiency of predicting therapeutic responsiveness by configuring, as appropriate parameters, blood and urine EDN levels together with the number of blood eosinophils that were conventionally used to predict therapeutic responsiveness to antibody therapeutic agents for asthma. Therefore, the present invention can be usefully utilized for predicting the therapeutic responsiveness of a subject to various antibody therapeutic agents for asthma, such as mepolyizumab, resluzumab, and dupilumab.

We provide antibody-based therapeutics against CD155 that can treat CNS cancers and systemic cancers. [Solution] Humanized antibodies or antigen-binding fragments specific to the poliovirus receptor (PVR) are used to prepare antibody-drug conjugates (ADCs) that target nucleic acids, peptides, proteins, drugs, and radiopharmaceuticals to cancer cells. These antibodies can be used for checkpoint blockade, blocking PVR (CD155) from binding to TIGIT. Humanized antibodies are used either alone or in combination with other checkpoint inhibitors known in the art. Humanized antibodies modulate the PVR-DNAM-1 axis to upregulate DNAM1 (CD226) expression on T cells or NK cells, thereby restoring the immune surveillance mechanism. The antibodies are incorporated into CAR-T cells or CAR NK cells.

The invention relates to a B cell immune reset method of a non-integrated in-vivo panCAR based on circRNA, and belongs to the technical field of immunotherapy. The invention provides a B cell resetting preparation. The main component of the B cell resetting preparation is spot type circRNA (Ribonucleic Acid) for coding an anti-CD19 chimeric antigen receptor (Anti-CD19-CAR); firstly, RNA molecules capable of coding Anti-CD19-CAR are subjected to cyclization treatment, then the RNA molecules are loaded on an LNP carrier to form a compound, and the compound can be used for B cell / antibody removal. After the preparation is injected into a body, panCAR cells (including CAR-T, CAR-NK and CAR-Macrophage) can be generated, compared with an antibody therapy and a CAR-T cell therapy, more thorough and safer B cell resetting can be achieved, and the preparation has application potential in the aspects of treating autoimmune diseases and allergic asthma and delaying senescence.

The invention relates to the field of breast cancer treatment, in particular to a PDIA3 protein targeting monoclonal antibody and application of the PDIA3 protein targeting monoclonal antibody in breast cancer treatment. According to the present invention, the IgG antibody in tumors, lymph nodes and serum is detected by using the IP-MS technology, the breast cancer tumor antigen disulfide isomerase A3 (PDIA3) is screened by analyzing the characteristics of the IgG antibody, and it is proved that the PDIA3 antigen can induce the breast cancer mouse model to produce the local humoral immune response. Meanwhile, it is found that a PDIA3 specific monoclonal antibody based on memory B cell reconstruction in TLN shows potent immune effect activity, wherein an Ab88 antibody can mediate an ADCC / ADCP effect and inhibit tumor growth. In conclusion, the invention provides the local targeting antigen PDIA3 protein with antibody therapy transformation potential and the specific antibody Ab88 thereof, and a new choice is provided for accurate treatment of breast cancer.

The invention provides an immune-related adverse reaction marker and a kit. The immune-related adverse reaction marker and the kit can effectively predict immune-related adverse reaction caused by programmed death receptor 1 antibody / programmed death ligand antibody treatment. The immune-related adverse reaction marker comprises CCL20, CXCL11, CXCL10 or CXCL9, and the immune-related adverse reaction marker comprises CCL20, CXCL11, CXCL10 or CXCL9. The immune-related adverse reaction marker and the kit provided by the technical scheme of the invention can effectively predict immune-related adverse reactions, so that the immune-related adverse reactions can be conveniently intervened and treated.

Using protein structural probes one can identify tumor-induced or -produced (TIPS) factors that bind to therapeutic antibodies and change their dynamic structure, thereby negatively affecting their humoral immune functions as well as their pharmacologic activity. Using such protein structural probes and TIPS factors one can screen and identify inhibitors that can counter the binding of TIPS factors to affected therapeutic antibodies. These inhibitors can be used in the presence of a TIPS factor-susceptible antibody (TSA) for treating cancer. An inhibitor can be used alone or in combination with chemotherapy for treating cancer. Patients can be screened to identify those with low or no TIPS factor production as candidates for antibody therapy even in the case in which the antibody is a TSA. Conversely, those with high TIPS factor production are candidates for inhibitor therapy.

Methods of measuring the amount of singly- or multiply-phosphorylated p217+ tau protein in a sample are provided. Methods of detecting or diagnosing tauopathies, methods of determining the effectiveness of a treatment of a tauopathy, and methods of determining whether a subject is suitable for anti-p217+ tau antibody therapy are also provided. Also described are antibodies for use in the methods and kits comprising the antibodies.

To provide an alternative antibody therapy targeting glycan epitopes.SOLUTION: Provided is an antibody or antigen-binding portion thereof that binds to sialyl Lewis A (sLeA) and sialyl Lewis C (sLeC), wherein the binding affinity of the antibody or antigen-binding portion to sLeA is a KD of 60 μ M or less and the binding affinity to sLeC is a KD of 100 μ M or less. Also provided are polynucleotides, vectors, host cells, pharmaceutical compositions, and methods related thereto.SELECTED DRAWING: Figure 2C

The invention belongs to the technical field of biological medicines, and particularly relates to application of all-trans retinoic acid in improving the curative effect of a pd1 antibody. According to the invention, the retinoic acid and the immune checkpoint inhibitor are combined for use, so that obvious beneficial effects are shown in the preparation of antitumor drugs. The combined strategy can effectively enhance the treatment response of an immune checkpoint inhibitor (such as an anti-PD-1 antibody), and overcomes the common primary and secondary drug resistance problems in single-drug treatment of the immune checkpoint inhibitor. The retinoic acid is used as an epigenetic regulator, and can be used for converting'cold tumor 'into'hot tumor' by activating a retinoic acid receptor pathway, up-regulating expression of new antigens in tumor cells, improving a tumor immune microenvironment and promoting infiltration and activation of T cells, so that the sensitivity of immunotherapy is remarkably improved. In an ICB drug resistance model, the all-trans retinoic acid combined anti-PD-1 antibody can obviously inhibit tumor growth and prolong the lifetime, and has a wide clinical application prospect.

The invention provides application of an anti-FGL1 monoclonal antibody in preparation of drugs for treating pancreatic cancer liver metastasis, and belongs to the technical field of antibody drugs. The anti-FGL1 monoclonal antibody can be combined with FGL1 protein in a high-specificity mode, the action mechanism of the anti-FGL1 monoclonal antibody in pancreatic cancer liver metastasis treatment is verified through a tumor cell model, a patient-derived tumor organ model and a mouse pancreas in-situ tumor model, and the anti-FGL1 monoclonal antibody can be used for preparing potential drugs for treating pancreatic cancer liver metastasis. Meanwhile, the anti-cancer effects of the FGL1 monoclonal antibody in normal diet mice and high fat diet mice (fatty liver models) are compared, so that the applicable population of the antibody therapy is determined, and a scientific basis is provided for the treatment of the FGL1 monoclonal antibody in pancreatic cancer.

The invention relates to the technical field of biological products, in particular to a mutant of pre-fusion human metapneumovirus F protein and application of the mutant. The mutant is obtained by performing the following mutation on the basis of wild type pre-fusion human metapneumovirus F protein: amino acids at 86-112 sites or amino acids at 97-106 sites are replaced by flexible linkers. The application comprises the following steps: preparing a medicine for preventing or treating hMPV infection; preparing an immunogenic composition for inducing an organism to generate a neutralizing antibody aiming at the hMPV; preparing a reagent or a kit for detecting the hMPV antibody; screening or preparing an anti-hMPV antibody; and separating the hMPV specific B cells. The new pre-fusion human metapneumovirus F protein mutant is obtained through research and design, has remarkably better stability, expression level and affinity, can be used for hMPV diagnosis, antibody therapy and development of various vaccines, and has important application value.

The invention provides an antibody-exosome, a preparation method thereof and application of the antibody-exosome in preparation of ricin detoxification drugs, and belongs to the technical field of drug delivery and intracellular therapy. The antibody-exosome disclosed by the invention comprises a milk-derived exosome (mExo) and a single-domain antibody V9E1 of an anti-ricin A chain; the amino acid sequence of the V9E1 is as shown in SEQ ID NO. 1. V9E1 is loaded into a milk exosome by using a saponin perforation method to obtain a V9E1 antibody-exosome, and the antibody-exosome shows reliable biological safety in both cells and animal bodies; the cell survival rate can be obviously improved in a Vero cell acute poisoning model; after mice are poisoned by ricin for 2 hours and 6 hours, the survival rate of the mice can be remarkably improved; through continuous administration, all mice injected with ricin with a complete lethal dose can survive, liver and spleen tissues can be protected, and the method has the potential of replacing a traditional ricin antibody therapy.

The present invention relates to combination therapies for treating a solid tumour in a subject. The combination therapies comprise (a) an antibody, or antigen-binding portion thereof, that specifically binds to CD40, and (b) a further immunotherapeutic agent with efficacy in the treatment of cancer, which agent is not an anti-CD40 antibody or antigen-binding fragment thereof. The invention also relates to a kits and methods of using such therapies.

The present disclosure provides anti-CD19 antibodies for use in the treatment of various cancers. The anti-CD19 antibody is administered to cancer patients in a specific dose or dosing regimen.

Provided herein are methods for treatment and uses involving dosing of compositions containing NK cells deficient in expression of FcRγ chain (g-NK cells) engineered with a recombinant chimeric antigen receptor (CAR) in combination with a monoclonal antibody. Among the provided methods and uses are methods and uses for treating cancer, such as multiple myeloma or lymphoma.

The present application provides a compound useful as an effective ingredient of a therapeutic drug composition for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy. The present inventors have researched a compound useful as an effective ingredient of a therapeutic drug composition for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy, and have confirmed that a heteroaryl formamide compound has DGKζ (DGKzeta) inhibitory action, thereby completing the present application. The heteroaryl formamide compound of the present application has DGKζ inhibitory action, and can be used as a therapeutic agent for a cancer associated with immune cell activation or a cancer resistant to anti-PD-1 antibody / anti-PD-L1 antibody therapy.

To provide a method for delivering a therapeutic protein to the central nervous system for antibody-based therapy.SOLUTION: A method of expressing a bivalent binding member in a cell of the nervous system, the method comprising introducing into the cell an expression cassette encoding a polypeptide comprising an antibody heavy chain variable domain (VH), an antibody light chain variable domain (VL) and an IgGFc region, wherein the VH and the VL form an antigen binding site which specifically binds to a target protein, and wherein two molecules of the polypeptide, when expressed in a cell, form a disulphide-linked homodimeric bivalent binding member specific for the target protein.SELECTED DRAWING: None

To provide methods of identifying HIV patients sensitive to therapy with GP120 V3 glycan-directed antibodies.SOLUTION: A method of treating or preventing HIV in a human subject in need thereof comprises: a) identifying a human subject who is infected with an HIV or a population of HIV expressing a gp120 comprising the following amino acid residues: N332 glycan, D325, and one or more amino acid residues selected from the group consisting of T63, L179, T320, and H330, wherein SEQ ID NO: 4 is referred to in the amino acid positions; and b) administering to the subject an effective amount of an antibody or antigenbinding fragment thereof that competes with or comprises VH and VL regions that bind to an epitope of gp120 within the third variable loop (V3) and / or high mannose patch comprising a N332 oligomannose glycan.SELECTED DRAWING: None

The invention relates to the field of drug addiction, in particular to a Cend1 protein Lys48 site lactic acid antigen peptide, an antibody and application of the Cend1 protein Lys48 site lactic acid antigen peptide. The amino acid sequence of the Lys48 site lactic acid antigen peptide of the Cend1 protein is as shown in SEQ ID NO. 1; the antibody is prepared by taking a Cend1 protein Lys48 site lactic acid antigen peptide as an immunogen. The Cend1 protein Lys48 site lactic acid antigen peptide provided by the invention can be used as a potential key protein molecule for treating methamphetamine addiction, and has very important significance for guiding molecule and antibody therapy for preventing and treating drug addiction and preparing drugs aiming at target spots.